Mattia Arrigo1,2,3,4, Quynh A Truong5, Jackie Szymonifka5, Mercedes Rivas-Lasarte1, Heli Tolppanen1, Malha Sadoune1, Etienne Gayat1,2, Alain Cohen-Solal1,3, Frank Ruschitzka4, James L Januzzi6, Jagmeet P Singh6, Alexandre Mebazaa1,2,7. 1. INSERM UMR-S 942, Paris, France. 2. Department of Anesthesiology and Critical Care Medicine, APHP, Saint Louis and Lariboisière University Hospitals, 2, rue Ambroise Paré, Paris 75010, France. 3. Department of Cardiology, APHP, Lariboisière University Hospitals, Paris, France. 4. Division of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. 5. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, NY, USA. 6. Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 7. Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France.
Abstract
AIMS: Cardiac resynchronization therapy (CRT) induces reverse cardiac remodelling in heart failure (HF), but many patients receiving CRT remain non-responders. This study assessed the role of amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), mid-regional-pro-atrial natriuretic peptide (MR-proANP), and mid-regional-pro-adrenomedullin (MR-proADM) at the time of device implantation to predict favourable clinical course (CRT response and/or risk of MACE) in HF patients receiving CRT. METHODS AND RESULTS: A total of 137 HF patients were prospectively included. Blood was drawn from the coronary sinus (CS) at CRT implantation, and from a peripheral vein (PV) simultaneously and after 6 months. Clinical CRT response at 6 months and major adverse cardiovascular events (MACE) at 2 years were assessed. Baseline PV-levels of MR-proANP (202 vs. 318 pmol/L, P = 0.009) and MR-proADM (843 vs. 1112 pmol/L, P = 0.02) were lower in CRT responders compared with non-responders. At 6 months, CRT responders showed a decrease in MR-proANP levels, compared with an increase in non-responders (-32 vs. +7 pmol/L, P = 0.02). During the same period, NT-proBNP decreased by a similar way in responders and non-responders, while MR-proADM was unchanged in both groups. High baseline MR-proANP, either in PV (OR 0.41, 95% CI 0.24-0.71, P = 0.002) or CS (OR 0.32, 95% CI 0.15-0.70, P = 0.005) was associated with reduced likelihood of CRT response. Furthermore, PV and CS levels of NT-proBNP, MR-proANP, and MR-proADM were all associated with increased risk of 2-year MACE (all P < 0.01). CONCLUSION: Mid-regional-pro-atrial natriuretic peptide may assist prediction of clinical course in HF patients undergoing CRT implantation. Low circulating MR-proANP at the time of device implantation is associated with CRT response and more favourable outcome. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Cardiac resynchronization therapy (CRT) induces reverse cardiac remodelling in heart failure (HF), but many patients receiving CRT remain non-responders. This study assessed the role of amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), mid-regional-pro-atrial natriuretic peptide (MR-proANP), and mid-regional-pro-adrenomedullin (MR-proADM) at the time of device implantation to predict favourable clinical course (CRT response and/or risk of MACE) in HF patients receiving CRT. METHODS AND RESULTS: A total of 137 HF patients were prospectively included. Blood was drawn from the coronary sinus (CS) at CRT implantation, and from a peripheral vein (PV) simultaneously and after 6 months. Clinical CRT response at 6 months and major adverse cardiovascular events (MACE) at 2 years were assessed. Baseline PV-levels of MR-proANP (202 vs. 318 pmol/L, P = 0.009) and MR-proADM (843 vs. 1112 pmol/L, P = 0.02) were lower in CRT responders compared with non-responders. At 6 months, CRT responders showed a decrease in MR-proANP levels, compared with an increase in non-responders (-32 vs. +7 pmol/L, P = 0.02). During the same period, NT-proBNP decreased by a similar way in responders and non-responders, while MR-proADM was unchanged in both groups. High baseline MR-proANP, either in PV (OR 0.41, 95% CI 0.24-0.71, P = 0.002) or CS (OR 0.32, 95% CI 0.15-0.70, P = 0.005) was associated with reduced likelihood of CRT response. Furthermore, PV and CS levels of NT-proBNP, MR-proANP, and MR-proADM were all associated with increased risk of 2-year MACE (all P < 0.01). CONCLUSION: Mid-regional-pro-atrial natriuretic peptide may assist prediction of clinical course in HF patients undergoing CRT implantation. Low circulating MR-proANP at the time of device implantation is associated with CRT response and more favourable outcome. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2009-02-10 Impact factor: 24.094
Authors: Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas Journal: Europace Date: 2013-06-24 Impact factor: 5.214
Authors: Stephan von Haehling; Gerasimos S Filippatos; Jana Papassotiriou; Mariantonietta Cicoira; Ewa A Jankowska; Wolfram Doehner; Piotr Rozentryt; Corrado Vassanelli; Joachim Struck; Waldemar Banasiak; Piotr Ponikowski; Dimitrios Kremastinos; Andreas Bergmann; Nils G Morgenthaler; Stefan D Anker Journal: Eur J Heart Fail Date: 2010-03-09 Impact factor: 15.534
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: T Nishikimi; Y Saito; K Kitamura; T Ishimitsu; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka Journal: J Am Coll Cardiol Date: 1995-11-15 Impact factor: 24.094
Authors: Quynh A Truong; James L Januzzi; Jackie Szymonifka; Wai-ee Thai; Bryan Wai; Zachary Lavender; Umesh Sharma; Ryan M Sandoval; Zachary S Grunau; Sandeep Basnet; Adefolakemi Babatunde; Olujimi A Ajijola; James K Min; Jagmeet P Singh Journal: Heart Rhythm Date: 2014-07-08 Impact factor: 6.343
Authors: Mads J Andersen; Mads Ersbøll; John Bro-Jeppesen; Jacob E Møller; Christian Hassager; Lars Køber; Barry A Borlaug; Jens P Goetze; Finn Gustafsson Journal: J Card Fail Date: 2014-10-05 Impact factor: 5.712
Authors: Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt Journal: Cardiovasc Res Date: 2022-07-20 Impact factor: 13.081